Which has preferable valuation and earnings, NVAX or MRNA?

Novavax has higher earnings, but lower revenue than Moderna. Novavax is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $596.34M 2.06 $440.30M -$0.58 N/A Moderna $2.20B 9.73 -$2.82B -$8.15 N/A

Is NVAX or MRNA more profitable?

Novavax has a net margin of -14.73% compared to Moderna's net margin of -143.55%. Novavax's return on equity of -14.82% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% Moderna -143.55% -26.64% -19.32%

Does the media refer more to NVAX or MRNA?

In the previous week, Moderna had 7 more articles in the media than Novavax. MarketBeat recorded 14 mentions for Moderna and 7 mentions for Novavax. Novavax's average media sentiment score of 0.93 beat Moderna's score of 0.42 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, NVAX or OCGN?

Novavax has higher revenue and earnings than Ocugen. Novavax is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $596.34M 2.06 $440.30M -$0.58 N/A Ocugen $4.47M 91.74 -$67.85M -$0.24 N/A

Is NVAX or OCGN more profitable?

Ocugen has a net margin of 0.00% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% Ocugen N/A -127,987.80% -135.48%

Does the media refer more to NVAX or OCGN?

In the previous week, Novavax had 4 more articles in the media than Ocugen. MarketBeat recorded 7 mentions for Novavax and 3 mentions for Ocugen. Ocugen's average media sentiment score of 0.96 beat Novavax's score of 0.93 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, AZN or NVAX?

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $60.44B 4.33 $10.23B $6.66 25.33 Novavax $596.34M 2.06 $440.30M -$0.58 N/A

Is AZN or NVAX more profitable?

Astrazeneca has a net margin of 17.19% compared to Novavax's net margin of -14.73%. Astrazeneca's return on equity of 30.86% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.19% 30.86% 12.68% Novavax -14.73% -14.82% 1.23%

Does the media prefer AZN or NVAX?

In the previous week, Astrazeneca had 34 more articles in the media than Novavax. MarketBeat recorded 41 mentions for Astrazeneca and 7 mentions for Novavax. Novavax's average media sentiment score of 0.93 beat Astrazeneca's score of 0.92 indicating that Novavax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 28 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Novavax 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, JNJ or NVAX?

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Johnson & Johnson $94.19B 6.73 $26.80B $8.63 30.52 Novavax $596.34M 2.06 $440.30M -$0.58 N/A

Is JNJ or NVAX more profitable?

Johnson & Johnson has a net margin of 21.48% compared to Novavax's net margin of -14.73%. Johnson & Johnson's return on equity of 32.86% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Johnson & Johnson 21.48% 32.86% 13.41% Novavax -14.73% -14.82% 1.23%

Does the media favor JNJ or NVAX?

In the previous week, Johnson & Johnson had 106 more articles in the media than Novavax. MarketBeat recorded 113 mentions for Johnson & Johnson and 7 mentions for Novavax. Johnson & Johnson's average media sentiment score of 1.13 beat Novavax's score of 0.93 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 86 Very Positive mention(s) 11 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Positive Novavax 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, NVAX or PFE?

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $596.34M 2.06 $440.30M -$0.58 N/A Pfizer $63.31B 2.21 $7.77B $1.31 18.72

Is NVAX or PFE more profitable?

Pfizer has a net margin of 11.83% compared to Novavax's net margin of -14.73%. Pfizer's return on equity of 19.44% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% Pfizer 11.83% 19.44% 8.41%

Does the media favor NVAX or PFE?

In the previous week, Pfizer had 50 more articles in the media than Novavax. MarketBeat recorded 57 mentions for Pfizer and 7 mentions for Novavax. Novavax's average media sentiment score of 0.93 beat Pfizer's score of 0.84 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pfizer 38 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 6 Negative mention(s) 3 Very Negative mention(s) Positive

Novavax (NVAX) Competitors

$7.46 -0.36 (-4.60%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$7.46 +0.00 (+0.07%)

As of 07/24/2026 07:34 PM Eastern

Compare

NVAX vs. MRNA, OCGN, AZN, JNJ, and PFE

Should you buy Novavax stock or one of its competitors? MarketBeat compares Novavax with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novavax include Moderna (MRNA), Ocugen (OCGN), Astrazeneca (AZN), Johnson & Johnson (JNJ), and Pfizer (PFE).

How does Novavax compare to Moderna?

Novavax (NASDAQ:NVAX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Novavax has higher earnings, but lower revenue than Moderna. Novavax is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$596.34M	2.06	$440.30M	-$0.58	N/A
Moderna	$2.20B	9.73	-$2.82B	-$8.15	N/A

53.0% of Novavax shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Novavax has a net margin of -14.73% compared to Moderna's net margin of -143.55%. Novavax's return on equity of -14.82% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Moderna	-143.55%	-26.64%	-19.32%

Novavax currently has a consensus price target of $13.00, suggesting a potential upside of 74.26%. Moderna has a consensus price target of $40.00, suggesting a potential downside of 26.02%. Given Novavax's stronger consensus rating and higher probable upside, equities analysts clearly believe Novavax is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82

Novavax has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market. Comparatively, Moderna has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

In the previous week, Moderna had 7 more articles in the media than Novavax. MarketBeat recorded 14 mentions for Moderna and 7 mentions for Novavax. Novavax's average media sentiment score of 0.93 beat Moderna's score of 0.42 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Novavax beats Moderna on 11 of the 17 factors compared between the two stocks.

How does Novavax compare to Ocugen?

Novavax (NASDAQ:NVAX) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Novavax currently has a consensus target price of $13.00, indicating a potential upside of 74.26%. Ocugen has a consensus target price of $9.50, indicating a potential upside of 685.12%. Given Ocugen's stronger consensus rating and higher possible upside, analysts plainly believe Ocugen is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Novavax had 4 more articles in the media than Ocugen. MarketBeat recorded 7 mentions for Novavax and 3 mentions for Ocugen. Ocugen's average media sentiment score of 0.96 beat Novavax's score of 0.93 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocugen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novavax has higher revenue and earnings than Ocugen. Novavax is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$596.34M	2.06	$440.30M	-$0.58	N/A
Ocugen	$4.47M	91.74	-$67.85M	-$0.24	N/A

Novavax has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.18, suggesting that its stock price is 118% more volatile than the broader market.

Ocugen has a net margin of 0.00% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Ocugen	N/A	-127,987.80%	-135.48%

53.0% of Novavax shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Comparatively, 4.0% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Novavax beats Ocugen on 9 of the 17 factors compared between the two stocks.

How does Novavax compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and Novavax (NASDAQ:NVAX) are related companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Astrazeneca presently has a consensus price target of $211.00, suggesting a potential upside of 25.09%. Novavax has a consensus price target of $13.00, suggesting a potential upside of 74.26%. Given Novavax's higher probable upside, analysts plainly believe Novavax is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Astrazeneca has a net margin of 17.19% compared to Novavax's net margin of -14.73%. Astrazeneca's return on equity of 30.86% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.19%	30.86%	12.68%
Novavax	-14.73%	-14.82%	1.23%

In the previous week, Astrazeneca had 34 more articles in the media than Novavax. MarketBeat recorded 41 mentions for Astrazeneca and 7 mentions for Novavax. Novavax's average media sentiment score of 0.93 beat Astrazeneca's score of 0.92 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	28 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Novavax	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$60.44B	4.33	$10.23B	$6.66	25.33
Novavax	$596.34M	2.06	$440.30M	-$0.58	N/A

Astrazeneca has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Novavax has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market.

Summary

Astrazeneca beats Novavax on 11 of the 17 factors compared between the two stocks.

How does Novavax compare to Johnson & Johnson?

Johnson & Johnson (NYSE:JNJ) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	6.73	$26.80B	$8.63	30.52
Novavax	$596.34M	2.06	$440.30M	-$0.58	N/A

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Comparatively, 1.6% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Johnson & Johnson has a net margin of 21.48% compared to Novavax's net margin of -14.73%. Johnson & Johnson's return on equity of 32.86% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.48%	32.86%	13.41%
Novavax	-14.73%	-14.82%	1.23%

In the previous week, Johnson & Johnson had 106 more articles in the media than Novavax. MarketBeat recorded 113 mentions for Johnson & Johnson and 7 mentions for Novavax. Johnson & Johnson's average media sentiment score of 1.13 beat Novavax's score of 0.93 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	86 Very Positive mention(s)	11 Positive mention(s)	10 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Positive
Novavax	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Johnson & Johnson has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Novavax has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market.

Johnson & Johnson presently has a consensus price target of $265.30, indicating a potential upside of 0.71%. Novavax has a consensus price target of $13.00, indicating a potential upside of 74.26%. Given Novavax's higher probable upside, analysts plainly believe Novavax is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

Johnson & Johnson beats Novavax on 13 of the 16 factors compared between the two stocks.

How does Novavax compare to Pfizer?

Novavax (NASDAQ:NVAX) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

53.0% of Novavax shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 1.6% of Novavax shares are owned by company insiders. Comparatively, 0.6% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$596.34M	2.06	$440.30M	-$0.58	N/A
Pfizer	$63.31B	2.21	$7.77B	$1.31	18.72

Novavax currently has a consensus target price of $13.00, indicating a potential upside of 74.26%. Pfizer has a consensus target price of $28.50, indicating a potential upside of 16.21%. Given Novavax's stronger consensus rating and higher possible upside, equities research analysts clearly believe Novavax is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

Pfizer has a net margin of 11.83% compared to Novavax's net margin of -14.73%. Pfizer's return on equity of 19.44% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Pfizer	11.83%	19.44%	8.41%

Novavax has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market. Comparatively, Pfizer has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

In the previous week, Pfizer had 50 more articles in the media than Novavax. MarketBeat recorded 57 mentions for Pfizer and 7 mentions for Novavax. Novavax's average media sentiment score of 0.93 beat Pfizer's score of 0.84 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	38 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	3 Very Negative mention(s)	Positive

Summary

Pfizer beats Novavax on 10 of the 16 factors compared between the two stocks.

Get Novavax News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVAX vs. The Competition

Export

Metric	Novavax	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.23B	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-12.86	21.29	27.11	23.64
Price / Sales	2.06	161.63	511.13	89.90
Price / Cash	2.23	157.90	50.54	59.64
Price / Book	-9.44	7.88	10.28	6.07
Net Income	$440.30M	$23.86M	$3.60B	$331.99M
7 Day Performance	-9.14%	-3.82%	-1.27%	-0.63%
1 Month Performance	-12.85%	-2.61%	-0.37%	-2.00%
1 Year Performance	-0.13%	32.79%	18.30%	13.62%

Novavax Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVAX Novavax	2.1904 of 5 stars	$7.46 -4.6%	$13.00 +74.3%	-2.4%	$1.23B	$596.34M	N/A	1,990
MRNA Moderna	1.5742 of 5 stars	$59.49 -3.8%	$38.80 -34.8%	+59.0%	$23.61B	$1.94B	N/A	4,700	Upcoming Earnings Analyst Forecast
OCGN Ocugen	2.4203 of 5 stars	$1.33 -2.2%	$9.50 +614.3%	+8.0%	$450.23M	$4.41M	N/A	80	Upcoming Earnings
AZN Astrazeneca	4.5617 of 5 stars	$164.14 -2.8%	$211.00 +28.6%	+14.5%	$254.56B	$58.74B	24.65	96,100	Upcoming Earnings Short Interest Increase
JNJ Johnson & Johnson	4.2857 of 5 stars	$248.83 -1.7%	$265.30 +6.6%	+55.3%	$598.99B	$94.19B	28.83	138,200	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVAX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novavax (NVAX) Competitors